Relatedly, the presence of mutations, rearrangements, or duplications that hyperactivate telomerase are pathognomonic in numerous cancers, where they upregulate TERT through a variety of genetic and epigenetic mechanisms [187,188]. This evidence concerns the gene TERT and cancer.